PBS oral product
Naltrexone treatment information
Get Naltrexone
Evidence-led information about naltrexone in care for alcohol use disorder and opioid use disorder. Country guides separate clinical evidence, product status, funding, and access across eight health systems.
Naltrexone evidence by country
A clinical use, registered product, public funding, and pharmacy supply are different facts. Choose a country to see what current sources confirm.
Coverage varies
Canada
PHARMAC oral product
New Zealand
Contrave confirmed
Singapore
Two products listed
South Africa
Contrave confirmed
United Arab Emirates
Specialist pathway
United Kingdom
Oral and XR products
United States
Naltrexone at a glance
Useful orientation—not a promise of individual treatment results or local supply.
- Country evidence guides
- 8
- Common oral strength
- 50 mg
- US monthly injection
- 380 mg
- Established uses
- 2
Regulation, funding, product, and pathway checks
Standalone tablets used in many substance-use treatment protocols
Extended-release Vivitrol dose administered by a clinician
Alcohol use disorder and prevention of relapse to opioid use
What you will find on this site
The hub is organized around four evidence questions.
What does the medicine do?
Learn the pharmacology, approved uses, safety constraints, and limits of the clinical evidence—including the Sinclair Method, Contrave, and low-dose naltrexone.
What exists in this country?
Country guides check official labels, medicine registers, formularies, funding schedules, and treatment guidance without assuming regional availability.
What will still vary locally?
Coverage, pharmacy stock, clinician fees, eligibility, and individual suitability can change. Each guide identifies where local confirmation is still needed.
Where is the evidence?
Articles lead with a direct answer and key takeaways, then link to primary regulatory, payer, guideline, and clinical sources.
Latest treatment guides
In-depth articles about naltrexone treatment across the countries we cover.
Evidence & Access
Australia Naltrexone PBS Check: Item 8370M and 2026 Co-payments
PBS item 8370M covers naltrexone 50 mg tablets; 2026 maximum co-payments are $25 general and $7.70 concession.
2 minute read
Evidence & Access
Naltrexone and Liver Disease: What Current Evidence Shows
Observational studies are reassuring in many patients with liver disease and cirrhosis, but they do not make naltrexone risk-free or settle every decompensated-liver scenario.
3 minute read
Evidence & Access
New Zealand Naltrexone Funding: June 2026 PHARMAC Check
Naltraccord 50 mg is fully subsidised under SA1408, while pharmacy charges and GP fees remain separate.
2 minute read
Check naltrexone evidence where you live
Product status, funding, supply, and prescribing pathways differ. Choose a country to see the dated evidence and the questions that still need local confirmation.